These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients. Bairey O; Gabbay U; Blickstein D; Stark P; Prokocimer M; Epstein O; Shaklai M; Lahav J Hematol Oncol; 1997 Aug; 15(3):121-7. PubMed ID: 9600111 [TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Lévy R; Colonna P; Tourani JM; Gastaut JA; Brice P; Raphaël M; Taillan B; Andrieu JM Leuk Lymphoma; 1995 Feb; 16(5-6):451-6. PubMed ID: 7540459 [TBL] [Abstract][Full Text] [Related]
12. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy. Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202 [TBL] [Abstract][Full Text] [Related]
13. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. Tirelli U; Errante D; Dolcetti R; Gloghini A; Serraino D; Vaccher E; Franceschi S; Boiocchi M; Carbone A J Clin Oncol; 1995 Jul; 13(7):1758-67. PubMed ID: 7541452 [TBL] [Abstract][Full Text] [Related]
14. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
15. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease. Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562 [TBL] [Abstract][Full Text] [Related]
17. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma]. Kamieńska E Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116 [TBL] [Abstract][Full Text] [Related]
18. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Shapiro CL; Yeap BY; Godleski J; Jochelson MS; Shipp MA; Skarin AT; Canellos GP Cancer; 1991 Aug; 68(4):699-705. PubMed ID: 1713121 [TBL] [Abstract][Full Text] [Related]
19. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651 [TBL] [Abstract][Full Text] [Related]
20. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. Sawka CA; Shepherd FA; Brandwein J; Burkes RL; Sutton DM; Warner E Leuk Lymphoma; 1992 Oct; 8(3):213-20. PubMed ID: 1283356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]